Drug Safety and Pharmacovigilance Across the Product Lifecycle

Back to Agenda

Session 6: FDA Guidance for Industry on Safety Reporting

Session Chair(s)

Jill W. Buckley, PharmD

Adjunct Assistant Professor

Rutgers, the State University of New Jersey, United States

This session will review the FDA guidelines on safety reporting that provide recommendations for how sponsors of INDs can identify and evaluate important safety information as well as recommendations for a systematic approach to IND safety reporting.

Have an account?

Drug Safety and Pharmacovigilance Across the Product Lifecycle

Session 6: FDA Guidance for Industry on Safety Reporting

Session Chair(s)

Jill W. Buckley, PharmD

Be informed and stay engaged.